3
Announcements
Trials
Browse
Landscape
Phase
Phase 1
1
Status
Completed
1
Sponsor Class
INDUSTRY
1
Study Type
Interventional
1
Sponsor
Cancer Type
Thoracic
1
Other solid neoplasm
1
Other hematologic neoplasm
1
Myeloid
1
Gastrointestinal
1
Dermatologic
1
CNS
1
Conditions
Myelodysplastic Syndromes
2
Leukemia, Myeloid, Acute
2
Pancreatic Neoplasms
1
Mesothelioma, Malignant
1
Melanoma
1
Glioblastoma
1
Carcinoma, Non-Small-Cell Lung
1
COVID-19
1
Interventions
tipifarnib
1
ruxolitinib
1
ripretinib
1
peginterferon alfa-2a
1
cobimetinib
1
cc-486
1
bemcentinib
1
avelumab
1
Vemurafenib
1
Standard of Care
1
Quality of Life
1
Practice Guidelines as Topic
1
Pentetic Acid
1
Pemetrexed
1
Patient Reported Outcome Measures
1
Palliative Care
1
PLX8394
1
Nurse Clinicians
1
Molecular Diagnostic Techniques
1
Minocycline
1
Ipilimumab
1
Interferon alpha-2
1
Injections
1
In Situ Hybridization, Fluorescence
1
Immunotherapy
1
Imatinib Mesylate
1
Heparin
1
Fentanyl
1
Drug Therapy
1
Cisplatin
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Melanoma
×
bemcentinib
×
Myeloid
×
Clear all
NCT06469138
2025-01-29
8479217
BerGenBio ASA
Phase 1
Completed
6 enrolled
17 charts